PHARMACOKINETICS AND EFFICACY OF THE NEW PDE INHIBITOR MS54 IN ANIMAL MODELS OF AUTOIMMUNE DISEASES

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-PAA-006
• By: WYSKA, Elzbieta (Jagiellonian University Medical College, Department of Pharmacokinetics and Physical Pharmacy, Poland)
• Co-author(s): Elżbieta Wyska: Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Kraków, Poland
  Artur Świerczek: Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Kraków, Poland
  Krzysztof Pociecha: Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Kraków, Poland
  Marietta Ślusarczyk: Department of Medicinal Chemistry, Jagiellonian University Medical College, Kraków, Poland
  Grażyna Chłoń-Rzepa: Department of Medicinal Chemistry, Jagiellonian University Medical College, Kraków, Poland
  
• Abstract:

  Background

  Autoimmune diseases (AID) are chronic disorders of unknown etiology, often leading to disability and premature mortality. In search for new therapeutic options, selective phosphodiesterase (PDE) inhibitors have been tested using animal models of these diseases, however, up to date, none of them has been registered for this indication.

  Meth

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login